NCT06842524View on ClinicalTrials.gov

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
DRUG

Dihydroartemisinin

Dihydroartemisinin tablets 40mg tid po for 90 days

DRUG

Placebo

Identical placebo tid for 90 days

Trial Locations (4)

200032

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER